Pet Pharm Biotech Co (ROCO:7762) Shares Outstanding (EOP): 58.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
19 GF Score
Price NT$49.75
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co Shares Outstanding (EOP)?

Pet Pharm Biotech Co ROCO:7762 +1.19% 19 Shares Outstanding (EOP) is 58.1 Mil as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Pet Pharm Biotech Co's shares outstanding for the quarter that ended in Dec. 2025 was 58.1 Mil.

Pet Pharm Biotech Co's quarterly shares outstanding increased from Jun. 2025 (52.0 Mil) to Dec. 2025 (58.1 Mil). It means Pet Pharm Biotech Co issued new shares from Jun. 2025 to Dec. 2025 .

Pet Pharm Biotech Co's annual shares outstanding increased from Dec. 2024 (42.8 Mil) to Dec. 2025 (58.1 Mil). It means Pet Pharm Biotech Co issued new shares from Dec. 2024 to Dec. 2025 .


Pet Pharm Biotech Co  (ROCO:7762) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Pet Pharm Biotech Co Shares Outstanding (EOP) Related Terms


Pet Pharm Biotech Co Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Shares Outstanding (EOP) Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
42.79 42.79 42.79 58.09

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial 42.79 42.79 42.79 51.98 58.09

ROCO:7762 vs LLY, JNJ, ABBV: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pet Pharm Biotech Co Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's Shares Outstanding (EOP) falls into.


ROCO:7762
19GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 58.1 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a Shares Outstanding (EOP) of 58.1 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Pet Pharm Biotech Co and its competitors.
Is Pet Pharm Biotech Co's Shares Outstanding (EOP) too high?
Pet Pharm Biotech Co's current Shares Outstanding (EOP) is 58.1 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Shares Outstanding (EOP) compare to LLY and JNJ?
Pet Pharm Biotech Co's Shares Outstanding (EOP) of 58.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Shares Outstanding (EOP) is 58.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Shares Outstanding (EOP) of 58.1 Mil. The current Shares Outstanding (EOP) is 58.1 Mil. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Shares Outstanding (EOP) is 58.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score

Get the complete analysis for ROCO:7762

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.75
Price